Substance / Medication

Tremelimumab

Overview

Active Ingredient
tremelimumab
RxNorm CUI
2619313
Labeler: AstraZeneca Pharmaceuticals LPUpdated: 2024-07-24T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review.
Arru Caterina, De Miglio Maria Rosaria, Cossu Antonio et al. · Adv Ther · 2021
PMID: 34105088Meta-AnalysisFull text (PMC)
Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma.
Wang Erjian, Kang Dongwoo, Bae Kyun-Seop et al. · J Clin Pharmacol · 2014
PMID: 24737343Meta-Analysis
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
Rimassa Lorenza, Chan Stephen L, Sangro Bruno et al. · J Hepatol · 2025
PMID: 40222621RCT
A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.
Gaillard Stéphanie, Verma Neha, Berg Maureen et al. · Gynecol Oncol · 2025
PMID: 39951918RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tremelimumab (substance)
SNOMED CT
2054101000122107
UMLS CUI
C2351038
RxNorm CUI
2619313
Labeler
AstraZeneca Pharmaceuticals LP

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.